Damon Bass

2.2k total citations
28 papers, 1.4k citations indexed

About

Damon Bass is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Damon Bass has authored 28 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Rheumatology, 20 papers in Radiology, Nuclear Medicine and Imaging and 16 papers in Immunology. Recurrent topics in Damon Bass's work include Systemic Lupus Erythematosus Research (26 papers), Monoclonal and Polyclonal Antibodies Research (19 papers) and T-cell and B-cell Immunology (13 papers). Damon Bass is often cited by papers focused on Systemic Lupus Erythematosus Research (26 papers), Monoclonal and Polyclonal Antibodies Research (19 papers) and T-cell and B-cell Immunology (13 papers). Damon Bass collaborates with scholars based in United States, United Kingdom and Japan. Damon Bass's co-authors include David A. Roth, David Gordon, Greg Dennis, James Groark, Leslie J. Crofford, Maria Watson, Evelyn Sarnes, Myron Chu, C. Kleoudis and Anne E. Hammer and has published in prestigious journals such as Kidney International, Annals of the Rheumatic Diseases and Nephrology Dialysis Transplantation.

In The Last Decade

Damon Bass

28 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Damon Bass United States	14	1.1k	753	526	173	120	28	1.4k
Ling Yin Ho China	21	1.1k 1.0×	620 0.8×	176 0.3×	106 0.6×	54 0.5×	51	1.5k
M. Pétri United States	17	850 0.8×	607 0.8×	210 0.4×	61 0.4×	160 1.3×	27	1.2k
Konstantinos Tselios Canada	20	810 0.8×	540 0.7×	141 0.3×	65 0.4×	109 0.9×	55	1.1k
Laura Lisk United States	12	943 0.9×	344 0.5×	218 0.4×	759 4.4×	145 1.2×	17	1.3k
Beth‐Ann Shanker United States	8	860 0.8×	680 0.9×	98 0.2×	57 0.3×	115 1.0×	16	1.3k
Yulia Green United Kingdom	8	631 0.6×	380 0.5×	220 0.4×	254 1.5×	680 5.7×	15	1.4k
Íñigo Rúa‐Figueroa Spain	21	682 0.6×	396 0.5×	154 0.3×	35 0.2×	143 1.2×	84	1.1k
Chryssa Papasteriades Greece	17	444 0.4×	378 0.5×	140 0.3×	70 0.4×	128 1.1×	31	918
Sandra Navarra Philippines	9	531 0.5×	402 0.5×	154 0.3×	126 0.7×	28 0.2×	22	739
Álvaro Danza Uruguay	10	553 0.5×	282 0.4×	128 0.2×	57 0.3×	35 0.3×	35	763

Countries citing papers authored by Damon Bass

Since Specialization

Citations

This map shows the geographic impact of Damon Bass's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Damon Bass with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Damon Bass more than expected).

Fields of papers citing papers by Damon Bass

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Damon Bass. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Damon Bass. The network helps show where Damon Bass may publish in the future.

Co-authorship network of co-authors of Damon Bass

This figure shows the co-authorship network connecting the top 25 collaborators of Damon Bass. A scholar is included among the top collaborators of Damon Bass based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Damon Bass. Damon Bass is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bae, Sang‐Cheol, Damon Bass, Myron Chu, et al.. (2022). The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study. Arthritis Research & Therapy. 24(1). 46–46. 8 indexed citations

Brunner, Hermine I., Carlos Abud‐Mendoza, Masaaki Mori, et al.. (2021). Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open. 7(3). e001747–e001747. 19 indexed citations

Tanaka, Yoshiya, Sang‐Cheol Bae, Damon Bass, et al.. (2021). Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. RMD Open. 7(2). e001629–e001629. 18 indexed citations

Rovin, Brad H., Richard Furie, Y K Onno Teng, et al.. (2021). A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney International. 101(2). 403–413. 112 indexed citations

Bruce, Ian N, et al.. (2021). Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme. Lupus Science & Medicine. 8(1). e000459–e000459. 9 indexed citations

Ginzler, Ellen M., David D’Cruz, Richard Furie, et al.. (2021). Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. Arthritis & Rheumatology. 74(1). 112–123. 72 indexed citations

Henderson, Robert B., Angela R. Jones-Leone, Shaun Flint, et al.. (2020). The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis. Arthritis Research & Therapy. 22(1). 102–102. 28 indexed citations

Mahajan, Anadi, Justyna Amelio, Kerry Gairy, et al.. (2020). Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus. 29(9). 1011–1020. 115 indexed citations

Bass, Damon, et al.. (2020). P128 Efficacy of intravenous belimumab in children with systemic lupus erythematosus with markers of high disease activity: across-trial comparison with adult belimumab studies. Poster presentations. A91–A92. 1 indexed citations

10.

Tanaka, Yoshiya, et al.. (2019). Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial. Modern Rheumatology. 30(2). 313–320. 12 indexed citations

11.

D’Cruz, David, Kathleen Maksimowicz‐McKinnon, Jim C. Oates, et al.. (2019). 200 Efficacy and safety of belimumab in patients of black race with systemic lupus erythematosus: results from the EMBRACE study. Abstracts. A149.2–A150. 14 indexed citations

12.

Vollenhoven, Ronald van, William Stohl, Richard Furie, et al.. (2018). Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study. Lupus Science & Medicine. 5(1). e000288–e000288. 12 indexed citations

13.

Zhang, Fengchun, Sang‐Cheol Bae, Damon Bass, et al.. (2018). A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Annals of the Rheumatic Diseases. 77(3). 355–363. 224 indexed citations

14.

Tanaka, Yoshiya, Damon Bass, Myron Chu, et al.. (2018). Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial. Modern Rheumatology. 29(3). 452–460. 13 indexed citations

15.

Doria, Andrea, William Stohl, Andreas Schwarting, et al.. (2017). SAT0231 Safety of subcutaneous belimumab in patients with systemic lupus erythematosus: a 6-month open-label extension study. Annals of the Rheumatic Diseases. 76. 861–861. 3 indexed citations

16.

Tanaka, Yoshiya, Damon Bass, Myron Chu, et al.. (2017). 106 Effects of belimumab on corticosteroid use in a pivotal phase iii, randomised, placebo controlled study in subjects with systemic lupus erythematosus in north east asia. A45.2–A46. 2 indexed citations

17.

Stohl, William, Andreas Schwarting, Masato Okada, et al.. (2017). Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study. Arthritis & Rheumatology. 69(5). 1016–1027. 286 indexed citations

18.

Garris, Cindy, Priti Jhingran, Damon Bass, et al.. (2013). Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan. Journal of Medical Economics. 16(5). 667–677. 85 indexed citations

19.

Sarnes, Evelyn, et al.. (2011). Incidence and US Costs of Corticosteroid-Associated Adverse Events: A Systematic Literature Review. Clinical Therapeutics. 33(10). 1413–1432. 199 indexed citations

20.

Routh, A, et al.. (1994). Management of Brain Metastases: Past, Present, and Future. Southern Medical Journal. 87(12). 1218–1226. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact